Early Adoption of Dupilumab in the Medicare Population in 2017

Background: In March of 2017, dupilumab became the first FDA approved injectable biologic for treatment of moderate-to-severe atopic dermatitis (AD). As the first drug in this class for AD, dupilumab has revolutionized the disease’s treatment and improved patient outcomes significantly. Previous wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheraghlou, Shayan, Cohen, Jeffrey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: YJBM 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757055/
https://www.ncbi.nlm.nih.gov/pubmed/33380928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757055/
https://www.ncbi.nlm.nih.gov/pubmed/33380928

Ejemplares similares